Marciano Lee, MD
Advanced Heart Failure and Transplant Cardiology · Lexington, KYNPI 1033172077
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,851 of the $11,207 with a category attached, or 79.0%. It is spread thinly across 26 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations.
Across 125 payments — averaging $89.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
- AstraZeneca$1K
- Biotronik Inc.$794
- Kestra Medical Technology Services, Inc.$704
- Cvrx, Inc.$599
- plus $4K from 20 others
What the payments were for
- Travel & lodging$2,35721%
- Food & beverage$8,85179%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 18 | $2,679 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 21 | $1,651 |
| AstraZeneca | 11 | $1,036 |
| Biotronik Inc. | 3 | $794 |
| Kestra Medical Technology Services, Inc. | 25 | $704 |
| Cvrx, Inc. | 9 | $599 |
| Ancora Heart, Inc. | 4 | $404 |
| Boehringer Ingelheim | 4 | $365 |
| Medtronic | 3 | $347 |
| Endotronix, Inc. | 1 | $312 |
| Actelion Pharmaceuticals US, Inc. | 3 | $298 |
| Bridgebio Pharma, Inc. | 2 | $265 |
| United Therapeutics Corporation | 2 | $250 |
| E.r. Squibb & Sons, L.L.C. | 3 | $230 |
| Abbott | 2 | $214 |
| Abiomed | 3 | $212 |
| Penumbra, Inc. | 1 | $156 |
| Shockwave Medical, Inc | 1 | $141 |
| Teleflex LLC | 1 | $134 |
| Bayer | 1 | $125 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Pfizer | 1 | $65 |
| Novartis | 2 | $35 |
| Merck | 1 | $34 |
| Alkermes, Inc. | 1 | $19 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$1,608
- FARXIGA$476
- LifeVest$471
- Barostim Neo System$381
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$312
- AccuCinch$279
- Attruby$265
- UPTRAVI$213
- OPSUMIT$213
- Indigo System$156
- Assure WCD$153
- Impella$141
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$141
- LUX-Dx Insertable Cardiac Monitor$140
- MANTA$134
- COREVALVE EVOLUT R$131
- WAINUA$125
- LOKELMA$125
- Kerendia$125
- Watchman$125
How this compares
Too few advanced heart failure and transplant cardiology providers in Kentuckyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 89 | $1,961,823 |
| EntrestoSacubitril/Valsartan | 254 | $267,034 |
| JardianceEmpagliflozin | 100 | $98,246 |
| FarxigaDapagliflozin Propanediol | 105 | $96,635 |
| Eplerenone | 18 | $1,793 |
| Metoprolol Succinate | 132 | $1,501 |
| Spironolactone | 208 | $1,266 |
| Torsemide | 78 | $968 |
| Isosorbide Dinitrate | 18 | $662 |
| Losartan Potassium | 69 | $365 |
| Carvedilol | 68 | $362 |
| Furosemide | 99 | $245 |
| ClopidogrelClopidogrel Bisulfate | 14 | $190 |
| Atorvastatin Calcium | 12 | $180 |
| Hydralazine Hcl | 16 | $128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax | $65 | $1,961,82389 claims |
| NovartisEntresto | $35 | $267,034254 claims |
| Boehringer IngelheimJardiance | $365 | $98,246100 claims |
| AstraZenecaFarxiga | $1,036 | $96,635105 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Kentuckyon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Lexington
- Sonu AbrahamLexington$13K
- Andrew KolodziejLexington$7K
- Navin RajagopalanLexington$6K
- Maya IgnaszewskiLexington$6K
- Paul AnayaLexington$194
- Timothy RaymondFt Wright$88K
- Chioma ObiokoyeLouisville$14K
- Hareeprasad VongooruEdgewood$8K
- Amaninderapal GhotraEdgewood$8K
- Keerthy NarisettyEdgewood$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.